Kristine Ball
Directeur/Membre du Conseil chez ATRECA, INC.
Fortune : - $ au 30/04/2024
Profil
Kristine McClintock Ball is currently the Chief Executive Officer at Antiva Biosciences, Inc. and also holds the position of Chief Executive Officer & Director at Soteria Biotherapeutics, Inc. She is an Independent Director at Atreca, Inc. and a Director at the National Kidney Foundation of Northern California.
Previously, Dr. Ball served as the Chief Executive Officer & Director at Soteria Biotherapeutics, Inc. She was an Independent Director at Forty Seven, Inc. from 2018 to 2020.
She also worked as a Senior Manager at Ernst & Young LLP from 1998 to 2000 and as the Vice President-Finance at Exelixis, Inc. from 2000 to 2005.
Additionally, she held the position of CFO, Senior VP-Administration & Finance at KAI Pharmaceuticals, Inc. From 2017 to 2020, Dr. Ball served as the Chief Financial Officer & SVP-Corporate Strategy at Menlo Therapeutics, Inc. She was also the Chief Financial Officer & Senior Vice President at Relypsa, Inc. from 2012 to 2016.
Dr. Ball completed her undergraduate degree at Babson College.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ATRECA, INC. CLASS A
-.--% | 13/06/2023 | 0 ( -.--% ) | - $ | 30/04/2024 |
Postes actifs de Kristine Ball
| Sociétés | Poste | Début |
|---|---|---|
| ATRECA, INC. | Directeur/Membre du Conseil | 20/05/2020 |
| National Kidney Foundation of Northern California | Directeur/Membre du Conseil | - |
Antiva Biosciences, Inc.
 Antiva Biosciences, Inc. BiotechnologyHealth Technology Antiva Biosciences, Inc. is a biopharmaceutical company developing novel, topical therapeutics for the treatment of diseases caused by HPV infection. The company was founded by Karl Y. Hostetler in 2012 and is headquartered in South San Francisco, CA. | Directeur Général | 27/04/2023 |
Anciens postes connus de Kristine Ball
| Sociétés | Poste | Fin |
|---|---|---|
| FORTY SEVEN, INC. | Directeur/Membre du Conseil | 07/04/2020 |
| VYNE THERAPEUTICS INC. | Directeur Financier/CFO | 01/03/2020 |
| RELYPSA INC | Directeur Financier/CFO | 01/01/2016 |
| EXELIXIS, INC. | Directeur Financier/CFO | 01/01/2005 |
Ernst & Young LLP
 Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY. | Corporate Officer/Principal | 01/01/2000 |
Formation de Kristine Ball
| Babson College | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| EXELIXIS, INC. | Health Technology |
| ATRECA, INC. | Health Technology |
| Entreprise privées | 8 |
|---|---|
KAI Pharmaceuticals, Inc.
 KAI Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology KAI Pharmaceuticals, Inc. discovers and develops biopharmaceutical drugs. It is a multiple, novel clinical-stage programs in the areas of cardiovascular, renal, and pain. The company was founded in 2002 and is headquartered in South San Francisco, CA. | Health Technology |
Ernst & Young LLP
Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY. | Commercial Services |
Relypsa, Inc.
 Relypsa, Inc. Pharmaceuticals: MajorHealth Technology Relypsa, Inc. operates as a bio-pharmaceutical company, which engages in the development and commercialization of late-stage medicines in the iron deficiency, nephrology, and cardio-renal therapeutic areas. It offers Veltassa, a potassium binder approved for the treatment of hyperkalemia. The company was founded by Jerry M. Buysse, Gerrit Klaerner, Michael Burdick, Jay P. Shepard, Detlef F. Albrecht, George Tyson, Sandra I. Coufal and Vic Ciaravino on October 29, 2007 and is headquartered in Redwood City, CA. | Health Technology |
Menlo Therapeutics, Inc.
 Menlo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Menlo Therapeutics Inc. operates as biopharmaceutical company which is focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis. The company was founded by Ed F. Schnipper in October, 2011 and is headquartered in Bridgewater, CA. | Health Technology |
| National Kidney Foundation of Northern California | |
Forty Seven, Inc.
 Forty Seven, Inc. Pharmaceuticals: MajorHealth Technology Forty Seven, Inc. develops therapies that target cancer immune evasion pathways. It develops Hu5F9-G4, a monoclonal antibody against human CD47 that potentially has applications spanning multiple tumor types and treatment modalities. The company was founded by Irving L. Weissman, Ravi Majeti, Mark Chao and Jens-Peter Volkmer in 2014 and is headquartered in Menlo Park, CA. | Health Technology |
Soteria Biotherapeutics, Inc.
 Soteria Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Soteria Biotherapeutics, Inc. develops next-generation immunotherapies. Its development allows to control the activity of immunomodulatory therapeutics such as bi-specific T-cell engagers (BiTEs) and CAR T-cells.The company was founded by Zachary Hill and Alexander Martinko and is headquartered in San Francisco, CA. | Health Technology |
Antiva Biosciences, Inc.
Antiva Biosciences, Inc. BiotechnologyHealth Technology Antiva Biosciences, Inc. is a biopharmaceutical company developing novel, topical therapeutics for the treatment of diseases caused by HPV infection. The company was founded by Karl Y. Hostetler in 2012 and is headquartered in South San Francisco, CA. | Health Technology |
